Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Distinct retrosplenial cortex cell populations and their spike dynamics during ketamine-induced unconscious state.

Fox GE, Li M, Zhao F, Tsien JZ.

PLoS One. 2017 Oct 26;12(10):e0187198. doi: 10.1371/journal.pone.0187198. eCollection 2017.

2.

Longistyline C acts antidepressant in vivo and neuroprotection in vitro against glutamate-induced cytotoxicity by regulating NMDAR/NR2B-ERK pathway in PC12 cells.

Liu Y, Zhao N, Li C, Chang Q, Liu X, Liao Y, Pan R.

PLoS One. 2017 Sep 5;12(9):e0183702. doi: 10.1371/journal.pone.0183702. eCollection 2017.

3.

Behavioural Effects of Using Sulfasalazine to Inhibit Glutamate Released by Cancer Cells: A Novel target for Cancer-Induced Depression.

Nashed MG, Ungard RG, Young K, Zacal NJ, Seidlitz EP, Fazzari J, Frey BN, Singh G.

Sci Rep. 2017 Jan 25;7:41382. doi: 10.1038/srep41382.

4.

Investigational drugs in recent clinical trials for treatment-resistant depression.

Garay RP, Zarate CA Jr, Charpeaud T, Citrome L, Correll CU, Hameg A, Llorca PM.

Expert Rev Neurother. 2017 Jun;17(6):593-609. doi: 10.1080/14737175.2017.1283217. Epub 2017 Jan 29. Review.

PMID:
28092469
5.

S-Ketamine Rapidly Reverses Synaptic and Vascular Deficits of Hippocampus in Genetic Animal Model of Depression.

Ardalan M, Wegener G, Rafati AH, Nyengaard JR.

Int J Neuropsychopharmacol. 2017 Mar 1;20(3):247-256. doi: 10.1093/ijnp/pyw098.

6.

Pushing the threshold: How NMDAR antagonists induce homeostasis through protein synthesis to remedy depression.

Raab-Graham KF, Workman ER, Namjoshi S, Niere F.

Brain Res. 2016 Sep 15;1647:94-104. doi: 10.1016/j.brainres.2016.04.020. Epub 2016 Apr 26. Review.

7.

The effects of drugs on human models of emotional processing: an account of antidepressant drug treatment.

Pringle A, Harmer CJ.

Dialogues Clin Neurosci. 2015 Dec;17(4):477-87. Review.

8.

Ketamine infusion for patients receiving extracorporeal membrane oxygenation support: a case series.

Tellor B, Shin N, Graetz TJ, Avidan MS.

F1000Res. 2015 Jan 16;4:16. doi: 10.12688/f1000research.6006.1. eCollection 2015.

9.

Optogenetic stimulation of infralimbic PFC reproduces ketamine's rapid and sustained antidepressant actions.

Fuchikami M, Thomas A, Liu R, Wohleb ES, Land BB, DiLeone RJ, Aghajanian GK, Duman RS.

Proc Natl Acad Sci U S A. 2015 Jun 30;112(26):8106-11. doi: 10.1073/pnas.1414728112. Epub 2015 Jun 8.

10.

Pathogenesis of depression: Insights from human and rodent studies.

Ménard C, Hodes GE, Russo SJ.

Neuroscience. 2016 May 3;321:138-162. doi: 10.1016/j.neuroscience.2015.05.053. Epub 2015 May 30. Review.

11.
12.

Effects of nitric oxide-related compounds in the acute ketamine animal model of schizophrenia.

Kandratavicius L, Balista PA, Wolf DC, Abrao J, Evora PR, Rodrigues AJ, Chaves C, Maia-de-Oliveira JP, Leite JP, Dursun SM, Baker GB, Guimaraes FS, Hallak JE.

BMC Neurosci. 2015 Mar 7;16:9. doi: 10.1186/s12868-015-0149-3.

13.

Urine metabolomics in rats after administration of ketamine.

Wen C, Zhang M, Ma J, Hu L, Wang X, Lin G.

Drug Des Devel Ther. 2015 Feb 3;9:717-22. doi: 10.2147/DDDT.S76898. eCollection 2015.

14.

Ketamine for the treatment of depression in patients receiving hospice care: a retrospective medical record review of thirty-one cases.

Iglewicz A, Morrison K, Nelesen RA, Zhan T, Iglewicz B, Fairman N, Hirst JM, Irwin SA.

Psychosomatics. 2015 Jul-Aug;56(4):329-37. doi: 10.1016/j.psym.2014.05.005. Epub 2014 Jun 5.

15.

NMDA receptor modulators: an updated patent review (2013-2014).

Strong KL, Jing Y, Prosser AR, Traynelis SF, Liotta DC.

Expert Opin Ther Pat. 2014 Dec;24(12):1349-66. doi: 10.1517/13543776.2014.972938. Epub 2014 Oct 29. Review.

16.

Therapeutic modalities for treatment resistant depression: focus on vagal nerve stimulation and ketamine.

Shah A, Carreno FR, Frazer A.

Clin Psychopharmacol Neurosci. 2014 Aug;12(2):83-93. doi: 10.9758/cpn.2014.12.2.83. Epub 2014 Aug 12. Review.

17.

Failed response to repeat intravenous ketamine infusions in geriatric patients with major depressive disorder.

Szymkowicz SM, Finnegan N, Dale RM.

J Clin Psychopharmacol. 2014 Apr;34(2):285-6. doi: 10.1097/JCP.0000000000000090. No abstract available.

18.

Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response.

Murrough JW, Wan LB, Iacoviello B, Collins KA, Solon C, Glicksberg B, Perez AM, Mathew SJ, Charney DS, Iosifescu DV, Burdick KE.

Psychopharmacology (Berl). 2013 Sep 11. [Epub ahead of print]

19.

Sustained antidepressant response to ketamine.

Atigari OV, Healy D.

BMJ Case Rep. 2013 Aug 19;2013. pii: bcr2013200370. doi: 10.1136/bcr-2013-200370.

20.

Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial.

Irwin SA, Iglewicz A, Nelesen RA, Lo JY, Carr CH, Romero SD, Lloyd LS.

J Palliat Med. 2013 Aug;16(8):958-65. doi: 10.1089/jpm.2012.0617. Epub 2013 Jun 27.

Supplemental Content

Support Center